The firm is developing products suited for pharmaceutical development from biomarker discovery through companion diagnostics and disease monitoring.
The data included results from thousands of clinically tested samples showing frequent identification of clinically useful diagnostic and prognostic markers.
The company is focusing on hematological malignancies and looking to partner with pharmaceutical companies for companion diagnostics.
Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.
The partners will map genomic variation and study its effects on patient outcomes to provide a resource for the prognosis of cancer patients and to help guide treatment for them.
The deal covers tests based on bone marrow and peripheral blood for hematologic cancers.
One of four new research centers, the collaborative network will look to push genomic and cell therapy technologies into clinical trials.
The researchers discovered mutations in essentially the same genes and came to very similar conclusions with regard to the increased cancer risk.
NEW YORK (GenomeWeb) – NeoGenomics today reported a 37 percent year-over-year increase in its third quarter revenues.
NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Thursday that it has licensed four biomarkers from the University of Tokyo that are believed to play a role in the prognosis of patients with blood cancers.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.